American Association for Cancer Research
Browse
cir-22-0115_supplemental_st1_suppst1.pdf (41.1 kB)

Supplementary Data from Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand–Expressing Solid Tumors

Download (41.1 kB)
journal contribution
posted on 2023-04-04, 01:40 authored by Pradip Bajgain, Alejandro G. Torres Chavez, Kishore Balasubramanian, Lindsey Fleckenstein, Premal Lulla, Helen E. Heslop, Juan Vera, Ann M. Leen
Supplementary Data from Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand–Expressing Solid Tumors

Funding

National Institutes of Health (NIH)

American Cancer Society (ACS)

Cancer Prevention and Research Institute of Texas (CPRIT)

V Foundation for Cancer Research (VFCR)

Elsa U. Pardee Foundation (EUPF)

Adrienne Helis Malvin Medical Research Foundation

History

ARTICLE ABSTRACT

T-cell immunotherapy has demonstrated remarkable clinical outcomes in certain hematologic malignancies. However, efficacy in solid tumors has been suboptimal, partially due to the hostile tumor microenvironment composed of immune-inhibitory molecules. One such suppressive agent abundantly expressed in solid tumors is Fas ligand (FasL), which can trigger apoptosis of Fas-expressing effector cells such as T cells and natural killer (NK) cells. To alleviate this FasL-induced suppression of tumor-specific immune cells in solid tumors, we describe here the development of a Fas decoy that is secreted by engineered cells upon activation and sequesters the ligand, preventing it from engaging with Fas on the surface of effector cells. We further improved the immune-stimulatory effects of this approach by creating a Fas decoy and IL15 cytokine fusion protein, which enhanced the persistence and antitumor activity of decoy-engineered as well as bystander chimeric-antigen receptor (CAR) T cells in xenograft models of pancreatic cancer. Our data indicate that secreted Fas decoys can augment the efficacy of both adoptively transferred and endogenous tumor-specific effector cells in FasL-expressing solid tumors.

Usage metrics

    Cancer Immunology Research

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC